Vanguard Group
NVLN

Vanguard Group’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Vanguard Group’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-31,308
Closed -$110K – 4142
2018
Q1 		$110K Sell
31,308
-2,428
-7% -$10.3K ﹤0.01% 4023
2017
Q4 		$105K Buy
33,736
+3,572
+12% +$17.2K ﹤0.01% 3989
2017
Q3 		$212K Sell
30,164
-314
-1% -$2.52K ﹤0.01% 3907
2017
Q2 		$281K Buy
+30,478
New +$294K ﹤0.01% 3840
2017
Q1 		– Sell
-24,780
Closed -$208K – 4073
2016
Q4 		$208K Buy
+24,780
New +$220K ﹤0.01% 3882

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Vanguard Group's NVLN Position: Q2 2018 in Review

Vanguard Group sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2018, closing a stake of 31,308 shares — an estimated $110K sold.

Vanguard Group first reported a position in NVLN in Q4 2016 and held it in 5 quarters. The position peaked at $281K in Q2 2017. 53 funds tracked by Wall St. Rank hold NVLN as of Q2 2018.

  • Vanguard Group reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2018 after selling out during the quarter.
  • Vanguard Group sold 31,308 Novelion Therapeutics Inc. Common Shares shares in Q2 2018, an estimated $110K.
  • Vanguard Group first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 5 quarters.
  • Vanguard Group's Novelion Therapeutics Inc. Common Shares position peaked at $281K in Q2 2017.
  • 53 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2018.

Based on Vanguard Group's 13F filing for Q2 2018, filed 14 Aug 2018.